Avalyn Pharma Inc. Financing Cash Flow
Avalyn Pharma Inc. (AVLN) reported Financing Cash Flow of $331.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Avalyn Pharma Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $316.67M, a 252.31% increase year-over-year.
- Avalyn Pharma Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $14.86M.
- Avalyn Pharma Inc. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $89.88M.
- Avalyn Pharma Inc. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $0.00.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month |
|---|---|---|
| 2026-06-30 | $316.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $331.54M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $14.86M 10-Q · filed 2026-06-03 | |
| 2025-06-30 | $89.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $89.88M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |